Biotech | February 05, 2021
Biocon Biologics to offer its oncology biosimilars in 30+ countries
The partnership is a significant step in delivering advanced cancer therapies to patients.
The partnership is a significant step in delivering advanced cancer therapies to patients.
The company has posted net profit of Rs.19.8 crores for the period ended December 31, 2020 as against net loss of Rs. 569.7 crores for the period ended December 31, 2019.
EBITDA for the quarter stood at Rs. 427 crore and Net Profit was at Rs. 169 crore. Our Core EBITDA margins stood at 31%.
The phase 3 clinical trial of Sputnik V will be conducted on 1,500 subjects as part of the randomized, double blind, parallel group placebo controlled study in India.
The company is expecting tremendous growth and a better quarterly performance
The Phase 2 study of Sputnik V was conducted on 100 subjects as part of the randomized, double-blind, parallel-group, placebo-controlled study in India.
Lasa Supergenerics Limited has received WHO GMP Certificate for its manufacturing facility situated at Khed in Ratnagiri.
Their feedback and the consequent changes in software/protocols based on those inputs were deliberated upon.
Biocon Ltd, an innovation-led global biopharmaceuticals company, has announced that the Board of its subsidiary Biocon Biologics Ltd has approved a primary equity investment of US $75 million (Rs. 555 crores) by Abu Dhabi based ADQ, one of the region’s largest holding companies.
Strides Pharma Science Limited is pleased to announce that Aditya Puri joins the Strides Group as an Advisor and also will be a Director of its associate Company, Stelis Biopharma.
Subscribe To Our Newsletter & Stay Updated
